Hosted on MSN9h
Could CAR-T Therapy Be the End of Lifelong Lupus Medication? Early Results Say ‘Yes’However, a new CAR-T cell therapy called obecabtagene autoleucel could change this situation. CAR-T therapy (Chimeric Antigen ...
Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
A recent meta-analysis investigating cardiovascular complications in adults undergoing chimeric antigen receptor (CAR) T-cell ...
MedPage Today on MSN6d
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid TumorsOpens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...
Marker Therapeutics was awarded a $2 million grant from NIH Small Business Innovation Research Program (SBIR) to support the clinical investigation of MT-601 in patients with lymphoma who have ...
Suppose a cancer patient has been told that he would be free of cancer cells and return to his normal life; that would be the ...
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ...
News Medical on MSN9d
Modulating CD39 expression to enhance CAR-T cell therapy against hepatocellular carcinomaIn the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in ...
PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback